- Home
- NMM vs PHVS Comparison
NMM vs PHVS Comparison
Compare NMM & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMM
- PHVS
- Stock Information
- Founded
- NMM 2007
- PHVS 2015
- Country
- NMM Greece
- PHVS Switzerland
- Employees
- NMM N/A
- PHVS N/A
- Industry
- NMM Marine Transportation
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- NMM Consumer Discretionary
- PHVS Health Care
- Exchange
- NMM Nasdaq
- PHVS Nasdaq
- Market Cap
- NMM 959.8M
- PHVS 909.5M
- IPO Year
- NMM 2007
- PHVS 2021
- Fundamental
- Price
- NMM $41.00
- PHVS $16.64
- Analyst Decision
- NMM Strong Buy
- PHVS Buy
- Analyst Count
- NMM 1
- PHVS 6
- Target Price
- NMM $80.00
- PHVS $37.17
- AVG Volume (30 Days)
- NMM 88.6K
- PHVS 62.5K
- Earning Date
- NMM 05-07-2025
- PHVS 05-13-2025
- Dividend Yield
- NMM 0.49%
- PHVS N/A
- EPS Growth
- NMM N/A
- PHVS N/A
- EPS
- NMM 11.16
- PHVS N/A
- Revenue
- NMM $1,319,623,000.00
- PHVS N/A
- Revenue This Year
- NMM N/A
- PHVS N/A
- Revenue Next Year
- NMM $7.93
- PHVS N/A
- P/E Ratio
- NMM $3.61
- PHVS N/A
- Revenue Growth
- NMM 0.28
- PHVS N/A
- 52 Week Low
- NMM $28.37
- PHVS $11.51
- 52 Week High
- NMM $65.89
- PHVS $25.50
- Technical
- Relative Strength Index (RSI)
- NMM 62.92
- PHVS 48.94
- Support Level
- NMM $39.87
- PHVS $16.31
- Resistance Level
- NMM $42.49
- PHVS $17.53
- Average True Range (ATR)
- NMM 1.07
- PHVS 1.12
- MACD
- NMM 0.06
- PHVS -0.04
- Stochastic Oscillator
- NMM 65.53
- PHVS 27.06
About NMM Navios Maritime Partners LP Common Units Representing Limited Partner Interests
Navios Maritime Partners LP is a seaborne shipping company. It owns and operates dry cargo and container vessels with the primary long-term and staggered expiration charters. The firm's fleet consists of Ultra- Handymax, Panamax, Capsize, and Container vessels and categorized in Drybulk and Container vessels. It earns revenue through the chartering of vessels and voyage contracts. Geographically, it generates majority revenue from Asia.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.